H.R. 3996: Medicare Transaction Fraud Prevention Act

This bill, titled the Medicare Transaction Fraud Prevention Act, aims to establish a pilot program within the Medicare system to help prevent fraud related to durable medical equipment and clinical diagnostic laboratory tests. The main components of the bill are as follows:

Establishment of a Pilot Program

The bill mandates the Secretary of Health and Human Services to create a pilot program that will test a predictive risk-scoring algorithm. This algorithm will be used to oversee transactions related to:

• Durable medical equipment
• Clinical diagnostic laboratory tests

Duration and Scope

The program is planned to last for two years, beginning no later than January 1, 2026. It will focus on transactions involving Medicare beneficiaries who opt-in to participate and receive electronic Medicare Summary Notices.

Beneficiary Participation

Participation in the pilot program by beneficiaries is voluntary. Those who choose to participate can opt out anytime. To be included, beneficiaries must agree to receive electronic notifications and participate according to the program's guidelines.

Risk Scoring and Transaction Assessment

The predictive risk-scoring algorithm will assign risk scores to transactions based on factors such as:

• Prior relationships between beneficiaries and providers
• Billing patterns of providers
• Changes in electronic fund transfers
• Ownership changes of service providers

These risk scores will help identify and evaluate potentially fraudulent transactions.

Collaboration and Development

The Secretary will collaborate with industry representatives, including suppliers of durable medical equipment, to develop and implement the algorithm and the pilot program.

Implementation of the Algorithm

Before any algorithm is put into use, it must undergo testing and evaluation to ensure its accuracy and effectiveness. The Secretary is tasked with notifying beneficiaries and providers about how their data is used and informing them of their rights within the program.

Transaction Suspension Protocols

If a transaction is flagged as high-risk, the program will allow the Secretary to:

• Review the transaction for potential suspension
• Notify beneficiaries involved and allow them to respond to any erroneous assessments
• Send subsequent electronic notifications about high-risk transactions
• Provide information on how to report suspected fraud

Review Process

Any decision to suspend a transaction will involve human review alongside the algorithm's findings, ensuring that errors can be corrected and that legitimate claims are not unduly affected.

Definitions

The bill also includes definitions for key terms such as:

• Applicable item or service: Refers to durable medical equipment and clinical laboratory tests.
• Relevant transaction: A claim for payment involving these items or services rendered to participating beneficiaries.

Relevant Companies

• MDT - Medtronic plc: As a leading manufacturer of medical devices, changes in oversight may affect how their products are billed under Medicare.
• ABT - Abbott Laboratories: As a supplier of diagnostic laboratory tests, they may need to adapt to stricter payment oversight under the pilot program.
• BDX - Becton, Dickinson and Company: This company provides various medical devices that may require compliance with new billing protocols introduced in this bill.